Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Su-I Lin"'
Autor:
Hung-Ju Hsu, Chao-Ping Tung, Chung-Ming Yu, Chi-Yung Chen, Hong-Sen Chen, Yu-Chuan Huang, Pei-Hsun Tsai, Su-I Lin, Hung-Pin Peng, Yi-Kai Chiu, Yueh-Liang Tsou, Wei-Ying Kuo, Jhih-Wei Jian, Fei-Hung Hung, Chiao-Yun Hsieh, Michael Hsiao, Simon Shih-Hsien Chuang, Chia-Ning Shen, Yong Alison Wang, An-Suei Yang
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
Abstract Mesothelin (MSLN) is an attractive candidate of targeted therapy for several cancers, and hence there are increasing needs to develop MSLN-targeting strategies for cancer therapeutics. Antibody–drug conjugates (ADCs) targeting MSLN have be
Externí odkaz:
https://doaj.org/article/1fd9e8c33c85491783497a53a3cfc809
Autor:
Su, I-Lin1 (AUTHOR) ellen00418@gmail.com, Chen, Yen-Kung1,2 (AUTHOR) m004149@ms.skh.org.tw
Publikováno v:
Diagnostics (2075-4418). Jul2023, Vol. 13 Issue 13, p2293. 8p.
95
An explosive outbreak of HIV-1 circulating recombinant form (CRF) 07 BC among injection drug users (IDUs) has been observed in Taiwan since 2004. Currently, one of the most important issues for the prevention of such infection is to study the
An explosive outbreak of HIV-1 circulating recombinant form (CRF) 07 BC among injection drug users (IDUs) has been observed in Taiwan since 2004. Currently, one of the most important issues for the prevention of such infection is to study the
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/43033764793114060003
Autor:
Michael Hsiao, Jhih-Wei Jian, Chiao-Yun Hsieh, Yong Alison Wang, Yueh-Liang Tsou, Chia-Ning Shen, Yu Chung-Ming, Hung-Ju Hsu, Hong-Sen Chen, Kuo Wei-Ying, Fei-Hung Hung, Tung Chao-Ping, Chi-Yung Chen, Hung-Pin Peng, Pei-Hsun Tsai, Simon Shih-Hsien Chuang, An-Suei Yang, Chiu Yi-Kai, Su-I Lin, Yu-Chuan Huang
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
Scientific Reports
Scientific Reports
Mesothelin (MSLN) is an attractive candidate of targeted therapy for several cancers, and hence there are increasing needs to develop MSLN-targeting strategies for cancer therapeutics. Antibody–drug conjugates (ADCs) targeting MSLN have been demons
Autor:
Ching-Ping Tseng, Tsang Wu Liu, Chih Cheng Hsu, John T.A. Hsu, Su I. Lin, Chun Chun Cheng, Min Wu Chao, Hsing-Yi Chang, Hsian Yu Wang, Shiow Lin Pan, Han Chin Cheng, Yu Ling Chang, Shih Jen Liu, Hui Ju Tsai
Publikováno v:
Oncotarget
// Hsian-Yu Wang 1, 2 , Yu-Ling Chang 3 , Chun-Chun Cheng 4 , Min-Wu Chao 4 , Su-I Lin 5, 6 , Shiow-Lin Pan 4 , Chih-Cheng Hsu 3 , Tsang-Wu Liu 7 , Han-Chin Cheng 8, 9 , Ching-Ping Tseng 2 , Shih-Jen Liu 6, 10 , Hui-Ju Tsai 11, 12, 13 , Hsing-Yi Chan
Publikováno v:
American journal of cancer research. 9(9)
Cancer vaccine design to effectively eliminate tumors requires triggering strong immune reactions to elicit long-lasting humoral and cellular immunity and DNA vaccines have been demonstrated to be an attractive immunotherapeutic approach. The tumor-a
Autor:
Pei Hung Chuang, I. An Jen, Chun Yuan Lee, Yung Feng Yen, Su I. Lin, Yi Ming Arthur Chen, Marcelo Chen
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-7 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-7 (2019)
Highly active antiretroviral therapy (HAART) causes a rapid increase of CD4 + T cells counts during the first 3–6 months of treatment and may enhance the development of opportunistic infections (OIs). However, the short- and long-term effects of HA
Autor:
Shih-Jen Liu, Su-I Lin, Yu-Wen Chang, Steve R. Roffler, I-Hua Chen, Bing-Mae Chen, Ming-Hsi Huang, Yuh Pyng Sher
Publikováno v:
Cancer Letters. 377:126-133
Synthetic peptides are attractive for cancer immunotherapy because of their safety and flexibility. In this report, we identified a new B cell epitope of tumor-associated antigen L6 (TAL6) that could induce antibody-dependent cellular cytotoxicity (A
Autor:
Steve R. Roffler, Su-I Lin, Hsin Yu Liu, I-Ping Chiang, Yuh Pyng Sher, I-Hua Chen, Chen Yuan Lin, Shih-Jen Liu, Hsin-Wei Chen
Publikováno v:
Oncotarget
Cancer immunotherapy is attractive for antigen-specific T cell-mediated anti-tumor therapy, especially in induction of cytotoxic T lymphocytes. In this report, we evaluated human CTL epitope-induced anti-tumor effects in human lung cancer xenograft m
Publikováno v:
Annals of Oncology. 30:v23
Background Tumour associated antigen L6 (TAL6) is a cell surface protein of the transmembrane-4 superfamily (TM4SF) also known as TM4SF1. TAL6 is over-expressed in more than 80 % of human lung, breast, colon and ovarian tumours but not normal tissues